Sucampo Pharmaceuticals (SCMP) Set to Announce Quarterly Earnings on Tuesday
Sucampo Pharmaceuticals (NASDAQ:SCMP) will be posting its quarterly earnings results before the market opens on Tuesday, March 6th. Analysts expect Sucampo Pharmaceuticals to post earnings of $0.33 per share for the quarter.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $18.00 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $18.75. The company has a market capitalization of $839.46, a price-to-earnings ratio of -5.37, a price-to-earnings-growth ratio of 5.06 and a beta of 1.38.
Several research firms have recently weighed in on SCMP. BidaskClub upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Leerink Swann restated a “market perform” rating and issued a $15.00 price target on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Zacks Investment Research cut Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Nomura began coverage on Sucampo Pharmaceuticals in a research note on Monday, December 18th. They issued a “buy” rating and a $43.00 price target for the company. Finally, B. Riley boosted their price target on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Sucampo Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $20.25.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.